Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Recruiting
N/A
Interventional Study
Moxibustion
Hematopoietic Stem Cell Transplantation
Hemorrhagic Cystitis
Prevention
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 14 – 60
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 266 (estimated)
- Sponsor
- Yi Zhang · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxib…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patients are fully aware of the study, participate voluntarily and sign the informed consent form (ICF);
2. Age: 14-60 years;
3. Patients with pernicious blood diseases undergoing allo-HSCT using the MAC protocol or patients with severe aplastic anemia (Severe aplastic anemia…
Contacts